-
Researchers to share VESPER phase 2 clinical trial data
Investigators, including John B. Buse, MD, PhD, will discuss new insights from the VESPER program examining berobenatide, an ultra-long-acting glucagon-like peptide-1 (GLP-1) receptor agonist for weight management.
-
Experts to discuss the benefits of glucagon/GLP-1 receptor dual agonism gleaned from SYNCHRONIZE
Lee Kaplan, MD, PhD, and other investigators will examine the basic science underlying injectable survodutide, as well as results from two of the four studies in the SYNCHRONIZE program.
-
Authors of the Standards of Care in Diabetes—2026 will share insights on annual updates
This Saturday symposium, featuring Anne Peters, MD, Elizabeth Ann Beverly, PhD, Emily D. Szmuilowicz, MD, MS, and others, will cover chapters on diabetes technology, facilitating positive health behaviors, pharmacological approaches to glycemic management, cardiovascular disease and risk management, pregnancy, and diabetes in children and adolescents.
-
Experts to review the benefits and challenges of GLP-1 RAs beyond diabetes and obesity
Investigators will give an overview of new therapies coming into the market. Panelist Donna Ryan, MD, will discuss clinical trials for incretin-based therapies.
-
Panel discussion to track diabetes across diverse populations in the U.S.
Jithin Sam Varghese, PhD, MTech, and other panelists will delve into the epidemiology of diabetes, social roadblocks, and variations in health outcomes across the country amid changing national demographics.
-
Experts to reveal results of retatrutide trials TRANSCEND-T2D-1 and TRIUMPH-1
Jonathan Campbell, PhD, and other panelists will share new data and address how this triple-hormone receptor agonist may unlock the next frontier of treatment for obesity and type 2 diabetes.
-
Primary results for SOLSTICE and VISTA to be shared for the first time
Vanita R. Aroda, MD, and Melanie Davies, CBE, MBChB, MD, FRCP, FRCGP, FMedSci, will review the latest data for a novel oral glucagon-like peptide-1 receptor agonist in people living with with type 2 diabetes or overweight or obesity.
-
Presenters to provide first look at data from REIMAGINE trials of cagrilintide/semaglutide for type 2 diabetes management
John B. Buse, MD, PhD, and other researchers will share study results and a broad understanding of amylin, from the hormone’s biology to potential translation to clinical care via phase 3 trials.
-
Trending topics in diabetes and obesity research and care highlight the 2026 Scientific Sessions program
Experts from across the globe will offer new perspectives on obesity, artificial intelligence, liver disease, behavioral health, women’s health, nutrition, new technology, and other trending topics in diabetes this June in New Orleans.
-
New clinical trial results to debut daily in New Orleans
Investigators will present high-impact results for type 1 diabetes, type 2 diabetes, and obesity in several clinical trial sessions. Glucagon-like peptide-1 (GLP-1)-based therapies—including dual and triple agonists, oral agents, and longer acting formulations—will be a recurring topic.